BioMark Diagnostics Inc.
BUX
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.00K | 5.00K | 5.00K | 28.20K | 27.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.00K | 5.00K | 5.00K | 28.20K | 27.20K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 5.00K | 5.00K | 5.00K | 28.20K | 27.20K |
| SG&A Expenses | 78.10K | 155.50K | 149.00K | 144.40K | 174.70K |
| Depreciation & Amortization | 39.10K | 101.20K | 62.80K | 72.60K | 158.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 258.50K | 377.60K | 349.80K | 298.30K | 445.80K |
| Operating Income | -253.50K | -372.60K | -344.80K | -270.10K | -418.60K |
| Income Before Tax | -143.40K | -272.80K | -349.50K | -300.70K | -294.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -143.40K | -272.80K | -349.50K | -300.70K | -294.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -143.40K | -272.80K | -349.50K | -300.70K | -294.00K |
| EBIT | -253.50K | -372.60K | -344.80K | -270.10K | -418.60K |
| EBITDA | -250.50K | -369.70K | -341.90K | -267.30K | -416.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 105.09M | 105.09M | 105.09M | 105.09M | 105.09M |
| Average Diluted Shares Outstanding | 105.09M | 105.09M | 105.09M | 105.09M | 105.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |